LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 1556

Search options

  1. Article ; Online: Evaluating chest pain in patients with post COVID conditions permission to think outside of the box.

    Becker, Richard C

    Journal of thrombosis and thrombolysis

    2023  Volume 55, Issue 4, Page(s) 592–603

    Abstract: Chest pain is among the most common symptoms of post-COVID-19 Conditions (PCC) that prompts medical attention. Because the SARS-CoV-2 virus has proclivity for many organs and organ systems in the chest, ranging from the heart, lungs, great vessels, ... ...

    Abstract Chest pain is among the most common symptoms of post-COVID-19 Conditions (PCC) that prompts medical attention. Because the SARS-CoV-2 virus has proclivity for many organs and organ systems in the chest, ranging from the heart, lungs, great vessels, lymphatics, and peripheral nerves, clinicians evaluating patients with chest pain must consider a broad differential diagnosis and take a comprehensive approach to management.
    MeSH term(s) Humans ; SARS-CoV-2 ; COVID-19/complications ; COVID-19/diagnosis ; Post-Acute COVID-19 Syndrome ; Lung ; Chest Pain/diagnosis ; Chest Pain/etiology
    Language English
    Publishing date 2023-04-13
    Publishing country Netherlands
    Document type Editorial
    ZDB-ID 1230645-9
    ISSN 1573-742X ; 0929-5305
    ISSN (online) 1573-742X
    ISSN 0929-5305
    DOI 10.1007/s11239-023-02808-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease.

    Ali, Ahmed E / Becker, Richard C

    Journal of thrombosis and thrombolysis

    2024  

    Abstract: Anticoagulant therapy is a mainstay in the management of patients with cardiovascular disease and related conditions characterized by a heightened risk for thrombosis. Acute coronary syndrome, chronic coronary syndrome, ischemic stroke, and atrial ... ...

    Abstract Anticoagulant therapy is a mainstay in the management of patients with cardiovascular disease and related conditions characterized by a heightened risk for thrombosis. Acute coronary syndrome, chronic coronary syndrome, ischemic stroke, and atrial fibrillation are the most common. In addition to their proclivity for thrombosis, each of these four conditions is also characterized by local and systemic inflammation, endothelial/endocardial injury and dysfunction, oxidative stress, impaired tissue-level reparative capabilities, and immune dysregulation that plays a critical role in linking molecular events, environmental triggers, and phenotypic expressions. Knowing that cardiovascular disease and thrombosis are complex and dynamic, can the scientific community identify a common pathway or specific point of interface susceptible to pharmacological inhibition or alteration that is likely to be safe and effective? The contact factors of coagulation may represent the proverbial "sweet spot" and are worthy of investigation. The following review provides a summary of the fundamental biochemistry of factor XI, its biological activity in thrombosis, inflammation, and angiogenesis, new targeting drugs, and a pragmatic approach to managing hemostatic requirements in clinical trials and possibly day-to-day patient care in the future.
    Language English
    Publishing date 2024-04-25
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 1230645-9
    ISSN 1573-742X ; 0929-5305
    ISSN (online) 1573-742X
    ISSN 0929-5305
    DOI 10.1007/s11239-024-02985-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Factor XI: structure, function and therapeutic inhibition.

    Ali, Ahmed E / Becker, Richard C

    Journal of thrombosis and thrombolysis

    2024  

    Abstract: Arterial and venous thromboembolism is a major medical concern that requires therapeutic anticoagulation in various medical fields to prevent its drastic consequences. Despite significant advances in anticoagulant therapy, thrombosis remains a leading ... ...

    Abstract Arterial and venous thromboembolism is a major medical concern that requires therapeutic anticoagulation in various medical fields to prevent its drastic consequences. Despite significant advances in anticoagulant therapy, thrombosis remains a leading cause of morbidity and mortality worldwide. Traditional anticoagulants like heparin and vitamin K antagonists (VKAs) have shown efficacy in preventing and treating thrombosis but come with an inherent risk of bleeding due to their non-specific inhibition of multiple coagulation factors. Subsequent direct oral anticoagulants (DOACs), targeting specific factors such as Xa or thrombin, demonstrated improved safety profiles compared to VKAs, yet bleeding remains a concern. Accordingly, research is focused on developing anticoagulants with improved safety profiles. A safer class of anticoagulants would have broad appeal. The intrinsic pathway of coagulation, involving factor XI (FXI), has attracted attention as a potential target for safer anticoagulants. Preclinical studies and epidemiological data indicate that FXI deficiency or inhibition protects against thrombosis with minimal bleeding. Current research involves evaluating various FXI-directed strategies, and phase 2 studies have shown promising results in orthopedic surgery, atrial fibrillation, end-stage renal disease (ESRD), myocardial infarction, and ischemic stroke. Several agents, such as antisense oligonucleotides, monoclonal antibodies, small synthetic molecules, natural peptides, and aptamers, have been developed to inhibit FXI at different stages, offering potentially safer alternatives to traditional anticoagulants. However, the optimal balance between preventing thrombosis and the risk of bleeding associated with FXI inhibitors requires validation through extensive phase 3 clinical trials using definite clinical endpoints. Several of such trials are currently underway or planned to define the role of FXI inhibitors in clinical practice and determine the most suitable FXI inhibitor for each specific indication. The current review highlights the rationale behind developing FXI inhibitors, presenting the most advanced agents in development, summarizing completed clinical trials, and discussing ongoing research efforts.
    Language English
    Publishing date 2024-04-16
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 1230645-9
    ISSN 1573-742X ; 0929-5305
    ISSN (online) 1573-742X
    ISSN 0929-5305
    DOI 10.1007/s11239-024-02972-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Anticoagulation in Patients With COVID-19 Pneumonia-What Is the Optimal Intensity?

    Becker, Richard C / Ortel, Thomas L

    JAMA internal medicine

    2023  Volume 183, Issue 6, Page(s) 532–533

    MeSH term(s) Humans ; COVID-19 ; Blood Coagulation ; SARS-CoV-2 ; Anticoagulants/therapeutic use ; Anticoagulants/pharmacology
    Chemical Substances Anticoagulants
    Language English
    Publishing date 2023-03-20
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2699338-7
    ISSN 2168-6114 ; 2168-6106
    ISSN (online) 2168-6114
    ISSN 2168-6106
    DOI 10.1001/jamainternmed.2023.0625
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Factor Xa inhibitors: critical considerations for clinical development and testing.

    Becker, Richard C

    Journal of thrombosis and thrombolysis

    2021  Volume 52, Issue 2, Page(s) 397–402

    Abstract: The selection of factor (F) X and its activated protease FXa for targeted inhibition to prevent and treat thrombotic conditions is based on an understanding of coagulation biochemistry, sequential steps that occur on tissue factor bearing cells and the ... ...

    Abstract The selection of factor (F) X and its activated protease FXa for targeted inhibition to prevent and treat thrombotic conditions is based on an understanding of coagulation biochemistry, sequential steps that occur on tissue factor bearing cells and the interface of coagulation proteins, platelets, mononuclear cells and the nuclear constituents of inflammatory cells. The goal for developing direct oral FXa inhibitors was to achieve rapid, selective, predictable, safe and effective anticoagulation across a broad group of patients expected to derive benefit. The history and development in patient care are exemplars of knowledge, translation and collaboration between the public and private sectors.
    MeSH term(s) Anticoagulants/pharmacology ; Anticoagulants/therapeutic use ; Blood Coagulation/drug effects ; Blood Coagulation Factors/pharmacology ; Factor Xa/pharmacology ; Factor Xa Inhibitors/pharmacology ; Factor Xa Inhibitors/therapeutic use ; Humans ; Thrombosis
    Chemical Substances Anticoagulants ; Blood Coagulation Factors ; Factor Xa Inhibitors ; Factor Xa (EC 3.4.21.6)
    Language English
    Publishing date 2021-05-15
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 1230645-9
    ISSN 1573-742X ; 0929-5305
    ISSN (online) 1573-742X
    ISSN 0929-5305
    DOI 10.1007/s11239-021-02455-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: COVID-19 and its sequelae: a platform for optimal patient care, discovery and training.

    Becker, Richard C

    Journal of thrombosis and thrombolysis

    2021  Volume 51, Issue 3, Page(s) 587–594

    Abstract: COVID-19- related patient care and research have focused on short-term outcomes, particularly among those with underlying or preexisting medical conditions. A major focus has been on mortality rates. Broadening the dialogue is neither meant nor intended ... ...

    Abstract COVID-19- related patient care and research have focused on short-term outcomes, particularly among those with underlying or preexisting medical conditions. A major focus has been on mortality rates. Broadening the dialogue is neither meant nor intended to disparage the near-term devastation felt globally each day, but rather to begin preparation for optimally caring for and addressing the needs of survivors. The sequelae of COVID-19 includes acute, subacute and chronic stages of the condition. If one applies current World Health Organization (WHO) statistics to calculate the global burden of disease, there are 98,000,000 COVID-19 survivors. The following editorial focuses on post-COVID sequelae as a continuum of patient care needs, as well as discovery and training opportunities in an academic setting.
    MeSH term(s) Aftercare ; COVID-19/complications ; Chronic Disease ; Humans ; Survivors
    Language English
    Publishing date 2021-01-27
    Publishing country Netherlands
    Document type Editorial
    ZDB-ID 1230645-9
    ISSN 1573-742X ; 0929-5305
    ISSN (online) 1573-742X
    ISSN 0929-5305
    DOI 10.1007/s11239-021-02375-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Elite Reviewers 2019.

    Becker, Richard C

    Journal of thrombosis and thrombolysis

    2020  Volume 49, Issue 4, Page(s) 685–686

    Language English
    Publishing date 2020-04-09
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1230645-9
    ISSN 1573-742X ; 0929-5305
    ISSN (online) 1573-742X
    ISSN 0929-5305
    DOI 10.1007/s11239-020-02099-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor's page series.

    Becker, Richard C

    Journal of thrombosis and thrombolysis

    2021  Volume 52, Issue 3, Page(s) 692–707

    Abstract: The autonomic nervous system (ANS) is a complex network of nerves originating in the brain, brain stem, spinal cord, heart and extracardiac organs that regulates neural and physiological responses to internal and external environments and conditions. A ... ...

    Abstract The autonomic nervous system (ANS) is a complex network of nerves originating in the brain, brain stem, spinal cord, heart and extracardiac organs that regulates neural and physiological responses to internal and external environments and conditions. A common observation among patients with the 2019 Coronavirus (CoV) (SARS-severe acute respiratory syndrome CoV-2) (SARS-CoV-2) or COVID-19 [CO for corona, VI for virus, D for disease and 19 for when the outbreak was first identified (31 December 2019)] in the acute and chronic phases of the disease is tachycardia, labile blood pressure, muscular fatigue and shortness of breath. Because abnormalities in the ANS can contribute to each of these symptoms, herein a review of autonomic dysfunction in SARS-COV-2 infection is provided to guide diagnostic testing, patient care and research initiatives. The autonomic nervous system is a complex network of nerves originating in the brain, brain stem, spinal cord, heart and extracardiac organs that regulates neural and physiological responses to internal and external environments and conditions. A common collection of signs and symptoms among patients with the 2019 Coronavirus (CoV) (SARS-severe acute respiratory syndrome CoV-2) (SARS-CoV-2) or COVID-19 [CO for corona, VI for virus, D for disease and 19 for when the outbreak was first identified (31 December 2019)] is tachycardia, labile blood pressure, muscular fatigue and shortness of breath. Abnormalities in the autonomic nervous system (ANS) can contribute to each of these identifiers, potentially offering a unifying pathobiology for acute, subacute and the long-term sequelae of SARS-CoV-2 infection (PASC) and a target for intervention.
    MeSH term(s) Animals ; Autonomic Nervous System/physiopathology ; Autonomic Nervous System/virology ; Autonomic Nervous System Diseases/diagnosis ; Autonomic Nervous System Diseases/physiopathology ; Autonomic Nervous System Diseases/virology ; COVID-19/complications ; COVID-19/diagnosis ; COVID-19/physiopathology ; COVID-19/virology ; Host-Pathogen Interactions ; Humans ; Prognosis ; SARS-CoV-2/pathogenicity ; Time Factors
    Language English
    Publishing date 2021-08-17
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 1230645-9
    ISSN 1573-742X ; 0929-5305
    ISSN (online) 1573-742X
    ISSN 0929-5305
    DOI 10.1007/s11239-021-02549-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Anticipating the long-term cardiovascular effects of COVID-19.

    Becker, Richard C

    Journal of thrombosis and thrombolysis

    2020  Volume 50, Issue 3, Page(s) 512–524

    MeSH term(s) Betacoronavirus ; COVID-19 ; Cardio-Renal Syndrome/etiology ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/virology ; Coronavirus Infections/complications ; Humans ; Kidney Diseases/etiology ; Long-Term Care ; Pandemics ; Pneumonia, Viral/complications ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-09-03
    Publishing country Netherlands
    Document type Editorial ; Review
    ZDB-ID 1230645-9
    ISSN 1573-742X ; 0929-5305
    ISSN (online) 1573-742X
    ISSN 0929-5305
    DOI 10.1007/s11239-020-02266-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Toward understanding the 2019 Coronavirus and its impact on the heart.

    Becker, Richard C

    Journal of thrombosis and thrombolysis

    2020  Volume 50, Issue 1, Page(s) 33–42

    MeSH term(s) Animals ; Betacoronavirus/pathogenicity ; COVID-19 ; Coronavirus Infections/mortality ; Coronavirus Infections/physiopathology ; Coronavirus Infections/therapy ; Coronavirus Infections/virology ; Heart/physiopathology ; Heart/virology ; Heart Diseases/mortality ; Heart Diseases/physiopathology ; Heart Diseases/therapy ; Heart Diseases/virology ; Host-Pathogen Interactions ; Humans ; Pandemics ; Pneumonia, Viral/mortality ; Pneumonia, Viral/physiopathology ; Pneumonia, Viral/therapy ; Pneumonia, Viral/virology ; Prognosis ; Risk Assessment ; Risk Factors ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-04-20
    Publishing country Netherlands
    Document type Editorial ; Review
    ZDB-ID 1230645-9
    ISSN 1573-742X ; 0929-5305
    ISSN (online) 1573-742X
    ISSN 0929-5305
    DOI 10.1007/s11239-020-02107-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top